<article article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23322191</article-id><article-id pub-id-type="pmc">3566815</article-id><article-id pub-id-type="pii">bjc2012593</article-id><article-id pub-id-type="doi">10.1038/bjc.2012.593</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Epidural methadone results in dose-dependent analgesia in cancer pain, further enhanced by epidural dexamethasone</article-title><alt-title alt-title-type="running">Epidural methadone|dexamethasone for cancer pain</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lauretti</surname><given-names>G R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Rizzo</surname><given-names>C C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mattos</surname><given-names>A L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rodrigues</surname><given-names>S W</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1"><label>1</label><institution>Teaching Hospital, Department of Biomechanics, Medicine and Rehabilitation of Members of the Faculty of Medicine of Ribeir√£o Preto, University of S√£o Paulo</institution>, Av Bandeirantes 3900, Ribeir√£o Preto-S√£o Paulo 14039 900, Brazil</aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>E-mail: <email>grlauret@fmrp.usp.br</email></corresp></author-notes><pub-date pub-type="ppub"><day>05</day><month>02</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>15</day><month>01</month><year>2013</year></pub-date><volume>108</volume><issue>2</issue><fpage>259</fpage><lpage>264</lpage><history><date date-type="received"><day>28</day><month>05</month><year>2012</year></date><date date-type="rev-recd"><day>20</day><month>11</month><year>2012</year></date><date date-type="accepted"><day>10</day><month>12</month><year>2012</year></date></history><permissions><copyright-statement>Copyright ¬© 2013 Cancer Research UK</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Cancer Research UK</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/"><license-p>From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/</license-p></license></permissions><abstract><sec><title><offsets xml_i="3260" xml_f="3271" txt_i="11" txt_f="22">Background:</offsets></title><p><offsets xml_i="3282" xml_f="3416" txt_i="23" txt_f="157">This study was designed to evaluate the role of epidural methadone-lidocaine in cancer pain combined or not to epidural dexamethasone.</offsets></p></sec><sec><title><offsets xml_i="3438" xml_f="3446" txt_i="159" txt_f="167">Methods:</offsets></title><p><offsets xml_i="3457" xml_f="3535" txt_i="168" txt_f="246">In all, 72 cancer patients, 32- to 67-year-old were randomized to six groups (</offsets><italic><offsets xml_i="3543" xml_f="3544" txt_i="246" txt_f="247">n</offsets></italic><offsets xml_i="3553" xml_f="4123" txt_i="247" txt_f="817">=12) and prospectively studied to examine analgesia and adverse effects for 3 weeks. Patients received single-dose protocol epidural test drugs: Control group (CG) received epidural 40-mg lidocaine diluted to 10-ml volume with saline. Dexamethasone group (DG) 40-mg lidocaine plus 10-mg dexamethasone. The 2.5MetG 2.5-mg epidural methadone with 40-mg lidocaine; the 5MetG, 5-mg epidural methadone plus 40-mg lidocaine, the 7.5MetG, 7.5-mg epidural methadone plus 40-mg lidocaine and finally the 7.5Met-DexG, 7.5-mg methadone with 40-mg lidocaine and 10-mg dexamethasone.</offsets></p></sec><sec><title><offsets xml_i="4145" xml_f="4153" txt_i="819" txt_f="827">Results:</offsets></title><p><offsets xml_i="4164" xml_f="4395" txt_i="828" txt_f="1059">Groups CG, DG and 2.5MetG were similar regarding analgesia and side effects. Patients from 5MetG and 7.5MetG took 3¬±1 and 5¬±1 days, respectively, to restart oral morphine. Patients from 7.5MetDG took 14¬±2 to restart oral morphine (</offsets><italic><offsets xml_i="4403" xml_f="4404" txt_i="1059" txt_f="1060">P</offsets></italic><offsets xml_i="4413" xml_f="4506" txt_i="1060" txt_f="1150">&lt;0.001). Daily somnolence and appetite improved in the 7.5MetDG during 2-week evaluation (</offsets><italic><offsets xml_i="4514" xml_f="4515" txt_i="1150" txt_f="1151">P</offsets></italic><offsets xml_i="4524" xml_f="4604" txt_i="1151" txt_f="1228">&lt;0.005). Fatigue improved for both DG and 7.5MetDG during 2-week evaluation (</offsets><italic><offsets xml_i="4612" xml_f="4613" txt_i="1228" txt_f="1229">P</offsets></italic><offsets xml_i="4622" xml_f="4693" txt_i="1229" txt_f="1297">&lt;0.005). By the third week of evaluation, all patients were similar.</offsets></p></sec><sec><title><offsets xml_i="4715" xml_f="4727" txt_i="1299" txt_f="1311">Conclusions:</offsets></title><p><offsets xml_i="4738" xml_f="4882" txt_i="1312" txt_f="1456">Epidural methadone plus lidocaine resulted in dose-dependent analgesia, further improved by epidural dexamethasone, which also improved fatigue.</offsets></p></sec></abstract><kwd-group><kwd>cancer pain</kwd><kwd>epidural methadone</kwd><kwd>epidural dexamethasone</kwd></kwd-group></article-meta></front><body><p><offsets xml_i="5042" xml_f="5303" txt_i="1465" txt_f="1726">Spinal analgesics have been suggested as the fourth step in the World Health Organisation guidelines in the management of cancer pain for those patients who suffer from severe and refractory pain, or are incapable to bear the adverse effects from oral opioids (</offsets><xref ref-type="bibr" rid="bib4"><offsets xml_i="5336" xml_f="5366" txt_i="1726" txt_f="1756">Christo and Mazloomdoost, 2008</offsets></xref><offsets xml_i="5373" xml_f="5375" txt_i="1756" txt_f="1758">; </offsets><xref ref-type="bibr" rid="bib14"><offsets xml_i="5409" xml_f="5417" txt_i="1758" txt_f="1766">Hattori </offsets><italic><offsets xml_i="5425" xml_f="5430" txt_i="1766" txt_f="1771">et al</offsets></italic><offsets xml_i="5439" xml_f="5445" txt_i="1771" txt_f="1777">, 2009</offsets></xref><offsets xml_i="5452" xml_f="5558" txt_i="1777" txt_f="1883">). Although there are not sufficient clinical trials to evaluate spinal opioids in adult cancer patients (</offsets><xref ref-type="bibr" rid="bib22"><offsets xml_i="5592" xml_f="5599" txt_i="1883" txt_f="1890">Kurita </offsets><italic><offsets xml_i="5607" xml_f="5612" txt_i="1890" txt_f="1895">et al</offsets></italic><offsets xml_i="5621" xml_f="5627" txt_i="1895" txt_f="1901">, 2011</offsets></xref><offsets xml_i="5634" xml_f="6060" txt_i="1901" txt_f="2327">), morphine has been one of the cornerstones for the management of chronic intractable cancer pain. Due to the proximity to the receptor sites, the therapeutic efficacy of spinal opioid application lasts longer and also reduces systemic side effects. However, some patients unable to tolerate spinal morphine may suffer with side-effects from high doses. The opioid methadone has a broad-spectrum of suggested spinal actions: </offsets><italic><offsets xml_i="6068" xml_f="6069" txt_i="2327" txt_f="2328">Œº</offsets></italic><offsets xml_i="6078" xml_f="6097" txt_i="2328" txt_f="2347"> receptor agonist, </offsets><italic><offsets xml_i="6105" xml_f="6106" txt_i="2347" txt_f="2348">N</offsets></italic><offsets xml_i="6115" xml_f="6172" txt_i="2348" txt_f="2405">-methyl-ùíü-aspartate receptor (NMDA) receptor antagonist (</offsets><xref ref-type="bibr" rid="bib38"><offsets xml_i="6206" xml_f="6213" txt_i="2405" txt_f="2412">Sotgiu </offsets><italic><offsets xml_i="6221" xml_f="6226" txt_i="2412" txt_f="2417">et al</offsets></italic><offsets xml_i="6235" xml_f="6241" txt_i="2417" txt_f="2423">, 2009</offsets></xref><offsets xml_i="6248" xml_f="6268" txt_i="2423" txt_f="2443">), glial activator (</offsets><xref ref-type="bibr" rid="bib16"><offsets xml_i="6302" xml_f="6313" txt_i="2443" txt_f="2454">Hutchinson </offsets><italic><offsets xml_i="6321" xml_f="6326" txt_i="2454" txt_f="2459">et al</offsets></italic><offsets xml_i="6335" xml_f="6341" txt_i="2459" txt_f="2465">, 2010</offsets></xref><offsets xml_i="6348" xml_f="6464" txt_i="2465" txt_f="2581">), and has been increasingly used as a second-line opioid in recent years in the management of cancer-related pain (</offsets><xref ref-type="bibr" rid="bib24"><offsets xml_i="6498" xml_f="6511" txt_i="2581" txt_f="2594">Leppert, 2009</offsets></xref><offsets xml_i="6518" xml_f="6520" txt_i="2594" txt_f="2596">; </offsets><xref ref-type="bibr" rid="bib2"><offsets xml_i="6553" xml_f="6564" txt_i="2596" txt_f="2607">Anghelescu </offsets><italic><offsets xml_i="6572" xml_f="6577" txt_i="2607" txt_f="2612">et al</offsets></italic><offsets xml_i="6586" xml_f="6592" txt_i="2612" txt_f="2618">, 2011</offsets></xref><offsets xml_i="6599" xml_f="6601" txt_i="2618" txt_f="2620">; </offsets><xref ref-type="bibr" rid="bib27"><offsets xml_i="6635" xml_f="6651" txt_i="2620" txt_f="2636">Mercadante, 2012</offsets></xref><offsets xml_i="6658" xml_f="6786" txt_i="2636" txt_f="2764">). In addition, corticosteroids were described to be commonly used in cancer pain, in spite of its limited scientific evidence (</offsets><xref ref-type="bibr" rid="bib25"><offsets xml_i="6820" xml_f="6842" txt_i="2764" txt_f="2786">Leppert and Buss, 2012</offsets></xref><offsets xml_i="6849" xml_f="7045" txt_i="2786" txt_f="2982">). The purpose of the present study was to examine the potential role of epidural methadone in cancer pain therapy. Its efficacy was further evaluated by the association of epidural dexamethasone.</offsets></p><sec sec-type="materials|methods"><title><offsets xml_i="7090" xml_f="7111" txt_i="2983" txt_f="3004">Materials and methods</offsets></title><p><offsets xml_i="7122" xml_f="7438" txt_i="3005" txt_f="3321">The Ethics Committee at the University of S√£o Paulo's Teaching Hospital, Ribeir√£o Preto, approved the study protocol. After written informed consent, 72 from the total of 112 patients suffering from cancer pain were selected at the Pain Clinic (‚àº64% inclusion). The 72 patients were randomized to one of six groups (</offsets><italic><offsets xml_i="7446" xml_f="7447" txt_i="3321" txt_f="3322">n</offsets></italic><offsets xml_i="7456" xml_f="7649" txt_i="3322" txt_f="3515">=12) and prospectively studied using a placebo-controlled design to examine analgesia and adverse effects and assigned to treatments using a randomized number generator in a computer programme.</offsets></p><p><offsets xml_i="7656" xml_f="7794" txt_i="3516" txt_f="3654">The study was designed to have a power of 80% to detect a treatment difference of 1-day analgesia on a two-sided level of significance of </offsets><italic><offsets xml_i="7802" xml_f="7803" txt_i="3654" txt_f="3655">Œ±</offsets></italic><offsets xml_i="7812" xml_f="9066" txt_i="3655" txt_f="4909">=0.05 assuming a standard deviation of 2 days, and a minimum number of eight patients per group. Eligible patients were aged 32‚Äì67 year-old, with a diagnosis of cancer, documented history of moderate/severe, chronic cancer pain, classified as Tumour-Node-Metastasis stage III or IV, requiring round-the-clock opioid, and capacity to understand the study protocol. Patients were excluded from the study for the following reasons: evidence of clinically unstable disease, clinically significant gastro-intestinal disease, cyclic chemotherapy within 3 weeks before screening visit or planned during the core study (shown in the past to influence bowel function); radiotherapy that would influence bowel function or pain, refusal, allergy to any of the drugs used or inability to ingest the oral rescue analgesic morphine. The concept of a visual analogue scale (VAS), which consisted of a 10-cm line with 0 equalling ‚Äòno pain at all' and 10 equalling ‚Äòthe worst possible pain' was introduced. The patient brought the VAS scores and daily morphine consumption recorded each day at the weekly appointments (21-day study). However, patients were free to contact one of the authors anytime by a personal phone number, through a collect call, whenever necessary.</offsets></p><p><offsets xml_i="9073" xml_f="11912" txt_i="4910" txt_f="7740">All patients were regularly taking oral amitriptyline 25‚Äâmg at bedtime as part of our institutional protocol, and oral morphine regimen individually adjusted to a maximal oral dose of 80‚Äì90‚Äâmg per day, in order to keep the VAS score &lt;4/10. When patients complained of pain (VAS ‚â•4/10), despite the 80‚Äì90‚Äâmg daily oral morphine, they were submitted to the epidural test drugs and all patients were blind to the treatments. The day before the epidural test block was considered day-zero, and the day of the epidural block was performed was considered day-1 of the study. The groups were computer divided into six as follow: The Control group (CG) received epidural 40‚Äâmg lidocaine (1%, 20‚Äâml ampoule with no adrenaline, Cristalia) diluted to 10-ml volume with saline. The Dexamethasone group (DG) received 40‚Äâmg lidocaine plus 10‚Äâmg dexamethasone (8‚Äâmg dexamethasone acetate +2‚Äâmg dexamethasone phosphate, Ache). The 2.5MetG received 2.5‚Äâmg epidural methadone (Methadone, 1‚Äâml ampoule, dl-racemic mixture, 10‚Äâmg|ml, conservative-free, Cristalia) combined with 40‚Äâmg lidocaine; the 5MetG received 5‚Äâmg epidural methadone plus 40‚Äâmg lidocaine, the 7.5MetG received 7.5‚Äâmg epidural methadone plus 40‚Äâmg lidocaine and finally the 7.5Met-DG received 7.5‚Äâmg epidural methadone combined with 40‚Äâmg lidocaine and 10‚Äâmg dexamethasone. All patients received sacral block only, which was done under aseptic conditions always by the same anaesthetist that was unaware of the study drug prepared by a second anaesthetist. The drugs were diluted in a 10-ml covered syringe in order to keep the blindness of the study. The correct position of the needle as assessed by fluoroscopy and by injection of 1‚Äâml contrast (Omnipaque, 300‚Äâmg|ml iohexol, Sanofi). All sacral blocks were performed in the morning. Patients were free to manipulate their daily oral morphine consumption, in order to keep daily pain VAS&lt;4/10 and were followed on a weekly basis during 3 consecutive weeks. The 10‚Äâmg morphine tablets were given by the government. All patients registered once a day before bed-time (at 23-h) the VAS resembling the pain average of the day, the final daily consumption of oral morphine and the listed adverse effects. Patients assigned as ‚Äòyes' or ‚Äòno' the final impression of the side effects listed at the final of each week evaluation: (1) daily somnolence, (2) nocturnal insomnia, (3) nausea, (4) occurrence of vomiting, (5) constipation, (6) diminished appetite, (7) fatigue, (8) sadness. Complain of nausea &gt;3‚Äâcm in a 10‚Äâcm VAS and occurrence of vomiting was treated with 8‚Äâmg sublingual ondansetron two-three times daily, if necessary. Constipation was treated with improved ingest of fibres and/or oral laxative if necessary. Patients had free access to the personal cell phone of one of the authors that was unaware of the study groups.</offsets></p><sec><title><offsets xml_i="11928" xml_f="11948" txt_i="7741" txt_f="7761">Statistical analysis</offsets></title><p><offsets xml_i="11959" xml_f="12218" txt_i="7762" txt_f="8021">The normality of the distributions was assessed using the Shapiro‚ÄìWilk's test. Groups were compared for demographic data (age, weight, and height) by one-way ANOVA. Incidence of adverse events, gender and site of primary disease were compared among groups by </offsets><italic><offsets xml_i="12226" xml_f="12227" txt_i="8021" txt_f="8022">œá</offsets></italic><sup><offsets xml_i="12241" xml_f="12242" txt_i="8022" txt_f="8023">2</offsets></sup><offsets xml_i="12248" xml_f="12294" txt_i="8023" txt_f="8069"> analysis corrected for multiple comparisons. </offsets><italic><offsets xml_i="12302" xml_f="12303" txt_i="8069" txt_f="8070">P</offsets></italic><offsets xml_i="12312" xml_f="12492" txt_i="8070" txt_f="8247"> was considered significant if &lt;0.008. VAS scores; and the daily morphine consumption from day-zero to day-21 were compared among groups by two-way ANOVA for repeated measures (</offsets><xref ref-type="bibr" rid="bib6"><offsets xml_i="12525" xml_f="12550" txt_i="8247" txt_f="8272">Dexter and Chestnut, 1995</offsets></xref><offsets xml_i="12557" xml_f="12696" txt_i="8272" txt_f="8411">). The statistical analysis compared among the six different groups on each day of the study. Tukey Honest analysis was applied to correct </offsets><italic><offsets xml_i="12704" xml_f="12705" txt_i="8411" txt_f="8412">P</offsets></italic><offsets xml_i="12714" xml_f="12754" txt_i="8412" txt_f="8452"> values for multiple group comparisons. </offsets><italic><offsets xml_i="12762" xml_f="12763" txt_i="8452" txt_f="8453">P</offsets></italic><offsets xml_i="12772" xml_f="12859" txt_i="8453" txt_f="8537">&lt;0.05 was considered significant. Data are expressed as mean¬±s.d., otherwise stated.</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="12906" xml_f="12913" txt_i="8540" txt_f="8547">Results</offsets></title><p><offsets xml_i="12924" xml_f="13995" txt_i="8548" txt_f="9619">Four patients from the CG, 3 from the DG, 2 from the 2.5MetG, 5Met and 7.5Met G; and finally one from the 7.5MetDG were excluded from the final analysis due to incomplete data collection. However, the minimum of eight patients per group was maintained for statistical purposes. The exclusion reasons are detailed: three patients from the CG took their own decision to take oral codeine or diclofenac during the study period combined with oral morphine, while the remaining patient did not come to the last appointment. Related to the DG group, two patients forgotten to make notes related to VAS pain scores or oral morphine consumption, and other patient included by its own oral diclofenac during the study period. Two patients from 2.5MetG and 7.5MetG and 1 from the 5MetG were also excluded due to incomplete data collection regarding oral morphine consumption and pain VAS. One patient from 5MetG did not come to the last week appointment. Finally, 1 patient from the 7.5MetDG was excluded due to ingestion of oral metamizol for pain control during the study period.</offsets></p><p><offsets xml_i="14002" xml_f="14077" txt_i="9620" txt_f="9695">The groups showed no differences regarding gender, weight, age and height (</offsets><xref rid="tbl1" ref-type="table"><offsets xml_i="14111" xml_f="14118" txt_i="9695" txt_f="9702">Table 1</offsets></xref><offsets xml_i="14125" xml_f="14186" txt_i="9702" txt_f="9763">), distribution of the primary site of the cancer pathology (</offsets><xref rid="tbl2" ref-type="table"><offsets xml_i="14220" xml_f="14227" txt_i="9763" txt_f="9770">Table 2</offsets></xref><offsets xml_i="14234" xml_f="14295" txt_i="9770" txt_f="9831">) and incidence of metastasis, which varied from 60% to 73% (</offsets><italic><offsets xml_i="14303" xml_f="14304" txt_i="9831" txt_f="9832">P</offsets></italic><offsets xml_i="14313" xml_f="14323" txt_i="9832" txt_f="9839">&gt;0.05; </offsets><xref rid="tbl2" ref-type="table"><offsets xml_i="14357" xml_f="14364" txt_i="9839" txt_f="9846">Table 2</offsets></xref><offsets xml_i="14371" xml_f="14469" txt_i="9846" txt_f="9941">). In addition, all overall daily VAS scores were &lt;4‚Äâcm to all groups during the study period (</offsets><italic><offsets xml_i="14477" xml_f="14478" txt_i="9941" txt_f="9942">P</offsets></italic><offsets xml_i="14487" xml_f="14643" txt_i="9942" txt_f="10095">&gt;0.05, data not shown). On day-zero (day before the epidural test drugs) all patients were taking 80‚Äì90‚Äâmg oral morphine, as part of the study protocol (</offsets><italic><offsets xml_i="14651" xml_f="14652" txt_i="10095" txt_f="10096">P</offsets></italic><offsets xml_i="14661" xml_f="14819" txt_i="10096" txt_f="10248">&gt;0.05). On the following days, patients were free to take oral 10‚Äâmg morphine as much as necessary in order to keep pain VAS &lt;4|10‚Äâcm. Final VAS scores.</offsets></p><p><offsets xml_i="14826" xml_f="15082" txt_i="10249" txt_f="10505">On day-1 (the day patients were submitted to epidural test drugs), only the CG, DG and 2.5MetG kept the daily oral consumption of 80‚Äì90‚Äâmg morphine. These three groups gradually increased daily oral morphine consumption until day-21 (150‚Äì170‚Äâmg morphine) (</offsets><italic><offsets xml_i="15090" xml_f="15091" txt_i="10505" txt_f="10506">P</offsets></italic><offsets xml_i="15100" xml_f="15201" txt_i="10506" txt_f="10604">&gt;0.05). CG=DG=2.5MetG during all the 21-day evaluation regarding oral daily morphine consumption (</offsets><italic><offsets xml_i="15209" xml_f="15210" txt_i="10604" txt_f="10605">P</offsets></italic><offsets xml_i="15219" xml_f="15229" txt_i="10605" txt_f="10612">&gt;0.05; </offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="15261" xml_f="15269" txt_i="10612" txt_f="10620">Figure 1</offsets></xref><offsets xml_i="15276" xml_f="15278" txt_i="10620" txt_f="10622">).</offsets></p><p><offsets xml_i="15285" xml_f="15391" txt_i="10623" txt_f="10729">Related to the 5MetG, from day-1 to day-3, the daily intake of oral morphine was: 5MetG=7.5MetG=7.5MetDG (</offsets><italic><offsets xml_i="15399" xml_f="15400" txt_i="10729" txt_f="10730">P</offsets></italic><offsets xml_i="15409" xml_f="15437" txt_i="10730" txt_f="10752">&gt;0.05)&lt;CG=DG=2.5MetG (</offsets><italic><offsets xml_i="15445" xml_f="15446" txt_i="10752" txt_f="10753">P</offsets></italic><offsets xml_i="15455" xml_f="15632" txt_i="10753" txt_f="10927">&lt;0.001). From day-4, patients started getting daily increasing oral morphine intake, which was similar to the CG, DG and to the 2.5MetG from day-7 forwards (daily evaluation-</offsets><italic><offsets xml_i="15640" xml_f="15641" txt_i="10927" txt_f="10928">P</offsets></italic><offsets xml_i="15650" xml_f="15660" txt_i="10928" txt_f="10935">&gt;0.05; </offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="15692" xml_f="15700" txt_i="10935" txt_f="10943">Figure 1</offsets></xref><offsets xml_i="15707" xml_f="15832" txt_i="10943" txt_f="11068">). The evaluation of the 7.5MetG revealed that from day-1 to day-5, the daily intake of oral morphine was: 7.5MetG=7.5MetDG (</offsets><italic><offsets xml_i="15840" xml_f="15841" txt_i="11068" txt_f="11069">P</offsets></italic><offsets xml_i="15850" xml_f="15878" txt_i="11069" txt_f="11091">&gt;0.05)&lt;CG=DG=2.5MetG (</offsets><italic><offsets xml_i="15886" xml_f="15887" txt_i="11091" txt_f="11092">P</offsets></italic><offsets xml_i="15896" xml_f="16074" txt_i="11092" txt_f="11267">&lt;0.001). From day-6, patients started getting daily increasing oral morphine intake, which was similar to the CG, DG and to the 2.5MetG from day-10 forwards (daily evaluation-</offsets><italic><offsets xml_i="16082" xml_f="16083" txt_i="11267" txt_f="11268">P</offsets></italic><offsets xml_i="16092" xml_f="16102" txt_i="11268" txt_f="11275">&gt;0.05; </offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="16134" xml_f="16142" txt_i="11275" txt_f="11283">Figure 1</offsets></xref><offsets xml_i="16149" xml_f="16282" txt_i="11283" txt_f="11416">). Related to the 7.5MetDG, from day-1 to day-15, the daily intake of oral morphine was lesser when compared with the CG=DG=2.5MetG (</offsets><italic><offsets xml_i="16290" xml_f="16291" txt_i="11416" txt_f="11417">P</offsets></italic><offsets xml_i="16300" xml_f="16341" txt_i="11417" txt_f="11452">&lt;0.001). On day-4, 7.5MetDG&lt;5MetG (</offsets><italic><offsets xml_i="16349" xml_f="16350" txt_i="11452" txt_f="11453">P</offsets></italic><offsets xml_i="16359" xml_f="16401" txt_i="11453" txt_f="11489">&lt;0.05). On day-6, 7.5MetDG&lt;7.5MetG (</offsets><italic><offsets xml_i="16409" xml_f="16410" txt_i="11489" txt_f="11490">P</offsets></italic><offsets xml_i="16419" xml_f="16504" txt_i="11490" txt_f="11572">&lt;0.05). From day-15, the oral intake of daily morphine was similar to all groups (</offsets><italic><offsets xml_i="16512" xml_f="16513" txt_i="11572" txt_f="11573">P</offsets></italic><offsets xml_i="16522" xml_f="16532" txt_i="11573" txt_f="11580">&gt;0.05).</offsets></p><p><offsets xml_i="16539" xml_f="16588" txt_i="11581" txt_f="11630">The incidence of adverse effects is described in </offsets><xref rid="tbl3" ref-type="table"><offsets xml_i="16622" xml_f="16629" txt_i="11630" txt_f="11637">Table 3</offsets></xref><offsets xml_i="16636" xml_f="16781" txt_i="11637" txt_f="11782">. The complaints of gastric upsetting, constipation, sadness and nocturnal insomnia were similar among groups at day-7, -14 and -21 evaluations (</offsets><italic><offsets xml_i="16789" xml_f="16790" txt_i="11782" txt_f="11783">P</offsets></italic><offsets xml_i="16799" xml_f="16945" txt_i="11783" txt_f="11926">&gt;0.05). Related to all adverse effects questioned, daily somnolence and appetite improved in the 7.5MetDG during at day-7 and -14 evaluations (</offsets><italic><offsets xml_i="16953" xml_f="16954" txt_i="11926" txt_f="11927">P</offsets></italic><offsets xml_i="16963" xml_f="17042" txt_i="11927" txt_f="12003">&lt;0.005). Fatigue improved for both DG and 7.5MetDG during at day-7 and -14 (</offsets><italic><offsets xml_i="17050" xml_f="17051" txt_i="12003" txt_f="12004">P</offsets></italic><offsets xml_i="17060" xml_f="17141" txt_i="12004" txt_f="12082">&lt;0.005). However, all side effects were similar at the third week evaluation (</offsets><italic><offsets xml_i="17149" xml_f="17150" txt_i="12082" txt_f="12083">P</offsets></italic><offsets xml_i="17159" xml_f="17267" txt_i="12083" txt_f="12188">&gt;0.05). No other adverse effects rather than the questioned were spontaneously described by the patients.</offsets></p></sec><sec sec-type="discussion"><title><offsets xml_i="17311" xml_f="17321" txt_i="12190" txt_f="12200">Discussion</offsets></title><p><offsets xml_i="17332" xml_f="17891" txt_i="12201" txt_f="12760">In the present study, patients suffering from cancer pain treated chronically with oral morphine at round clock and amitriptyline before bedtime showed a dose-dependent analgesia after a single dose of 2.5, 5 and 7.5‚Äâmg epidural methadone, which was further increased by the addition of epidural dexamethasone. Previously, doses varying from daily epidural 12‚Äì32‚Äâmg methadone were formerly described to result in pain control in 80% of cancer patients suffering from visceral or somatic pain, with an average of 27-daily infusion and no serious side-effects (</offsets><xref ref-type="bibr" rid="bib37"><offsets xml_i="17925" xml_f="17930" txt_i="12760" txt_f="12765">Shir </offsets><italic><offsets xml_i="17938" xml_f="17943" txt_i="12765" txt_f="12770">et al</offsets></italic><offsets xml_i="17952" xml_f="17958" txt_i="12770" txt_f="12776">, 1991</offsets></xref><offsets xml_i="17965" xml_f="18134" txt_i="12776" txt_f="12945">). We used a single bolus of epidural racemic methadone for treating cancer pain, as the purpose of the study. Methadone was demonstrated to act primarily as agonist of </offsets><italic><offsets xml_i="18142" xml_f="18143" txt_i="12945" txt_f="12946">Œº</offsets></italic><offsets xml_i="18152" xml_f="18231" txt_i="12946" txt_f="13025">-opioid receptor, and its d isomer has also NMDA receptor antagonist activity (</offsets><xref ref-type="bibr" rid="bib18"><offsets xml_i="18265" xml_f="18280" txt_i="13025" txt_f="13040">Inturrisi, 2005</offsets></xref><offsets xml_i="18287" xml_f="18448" txt_i="13040" txt_f="13201">). It has high lipid solubility that could facilitate its entrance from the epidural space into the spine, although a peripheral action has also been described (</offsets><xref ref-type="bibr" rid="bib15"><offsets xml_i="18482" xml_f="18485" txt_i="13201" txt_f="13204">He </offsets><italic><offsets xml_i="18493" xml_f="18498" txt_i="13204" txt_f="13209">et al</offsets></italic><offsets xml_i="18507" xml_f="18513" txt_i="13209" txt_f="13215">, 2010</offsets></xref><offsets xml_i="18520" xml_f="18679" txt_i="13215" txt_f="13374">). Nevertheless, epidural methadone has an intrinsic spinal effect regardless of whether or not there is extra-spinal action arising from systemic absorption (</offsets><xref ref-type="bibr" rid="bib32"><offsets xml_i="18713" xml_f="18722" txt_i="13374" txt_f="13383">Parramon </offsets><italic><offsets xml_i="18730" xml_f="18735" txt_i="13383" txt_f="13388">et al</offsets></italic><offsets xml_i="18744" xml_f="18750" txt_i="13388" txt_f="13394">, 2003</offsets></xref><offsets xml_i="18757" xml_f="18759" txt_i="13394" txt_f="13396">).</offsets></p><p><offsets xml_i="18766" xml_f="18795" txt_i="13397" txt_f="13426">Epidural methadone combined (</offsets><xref ref-type="bibr" rid="bib35"><offsets xml_i="18829" xml_f="18844" txt_i="13426" txt_f="13441">Prieto-Alvarez </offsets><italic><offsets xml_i="18852" xml_f="18857" txt_i="13441" txt_f="13446">et al</offsets></italic><offsets xml_i="18866" xml_f="18872" txt_i="13446" txt_f="13452">, 2002</offsets></xref><offsets xml_i="18879" xml_f="18881" txt_i="13452" txt_f="13454">; </offsets><xref ref-type="bibr" rid="bib36"><offsets xml_i="18915" xml_f="18921" txt_i="13454" txt_f="13460">P√©rez </offsets><italic><offsets xml_i="18929" xml_f="18934" txt_i="13460" txt_f="13465">et al</offsets></italic><offsets xml_i="18943" xml_f="18949" txt_i="13465" txt_f="13471">, 2010</offsets></xref><offsets xml_i="18956" xml_f="18966" txt_i="13471" txt_f="13481">) or not (</offsets><xref ref-type="bibr" rid="bib32"><offsets xml_i="19000" xml_f="19009" txt_i="13481" txt_f="13490">Parramon </offsets><italic><offsets xml_i="19017" xml_f="19022" txt_i="13490" txt_f="13495">et al</offsets></italic><offsets xml_i="19031" xml_f="19037" txt_i="13495" txt_f="13501">, 2003</offsets></xref><offsets xml_i="19044" xml_f="19145" txt_i="13501" txt_f="13602">) to local anaesthetic has been described before as analgesic for acute pain in patients and horses (</offsets><xref ref-type="bibr" rid="bib30"><offsets xml_i="19179" xml_f="19203" txt_i="13602" txt_f="13626">Olbrich and Mosing, 2003</offsets></xref><offsets xml_i="19210" xml_f="19313" txt_i="13626" txt_f="13729">). Different combinations have been used in the actual multimodal cancer pain study. Clinically used Na</offsets><sup><offsets xml_i="19318" xml_f="19319" txt_i="13729" txt_f="13730">+</offsets></sup><offsets xml_i="19325" xml_f="19501" txt_i="13730" txt_f="13906"> channel blockers such as lidocaine, at doses which do not block conduction can relieve spinal sensitization and facilitator processes in dorsal horn neurons via blockade of Na</offsets><sup><offsets xml_i="19506" xml_f="19507" txt_i="13906" txt_f="13907">+</offsets></sup><offsets xml_i="19513" xml_f="19519" txt_i="13907" txt_f="13913"> and K</offsets><sup><offsets xml_i="19524" xml_f="19525" txt_i="13913" txt_f="13914">+</offsets></sup><offsets xml_i="19531" xml_f="19542" txt_i="13914" txt_f="13925"> channels (</offsets><xref ref-type="bibr" rid="bib31"><offsets xml_i="19576" xml_f="19587" txt_i="13925" txt_f="13936">Olschewski </offsets><italic><offsets xml_i="19595" xml_f="19600" txt_i="13936" txt_f="13941">et al</offsets></italic><offsets xml_i="19609" xml_f="19615" txt_i="13941" txt_f="13947">, 2009</offsets></xref><offsets xml_i="19622" xml_f="19718" txt_i="13947" txt_f="14043">), can directly modulate NMDA-receptor in the superficial dorsal horn, can inhibit persistent Na</offsets><sup><offsets xml_i="19723" xml_f="19724" txt_i="14043" txt_f="14044">+</offsets></sup><offsets xml_i="19730" xml_f="19780" txt_i="14044" txt_f="14094"> current in injured dorsal root ganglion neurons (</offsets><xref ref-type="bibr" rid="bib7"><offsets xml_i="19813" xml_f="19818" txt_i="14094" txt_f="14099">Dong </offsets><italic><offsets xml_i="19826" xml_f="19831" txt_i="14099" txt_f="14104">et al</offsets></italic><offsets xml_i="19840" xml_f="19846" txt_i="14104" txt_f="14110">, 2008</offsets></xref><offsets xml_i="19853" xml_f="20046" txt_i="14110" txt_f="14303">), and additionally may have a general glycine-like action of lidocaine or some of its metabolites on inhibitory strychnine-sensitive receptors and on strychnine-insensitive glycine receptors (</offsets><xref ref-type="bibr" rid="bib29"><offsets xml_i="20080" xml_f="20093" txt_i="14303" txt_f="14316">Muth-Selbach </offsets><italic><offsets xml_i="20101" xml_f="20106" txt_i="14316" txt_f="14321">et al</offsets></italic><offsets xml_i="20115" xml_f="20121" txt_i="14321" txt_f="14327">, 2009</offsets></xref><offsets xml_i="20128" xml_f="20130" txt_i="14327" txt_f="14329">; </offsets><xref ref-type="bibr" rid="bib10"><offsets xml_i="20164" xml_f="20173" txt_i="14329" txt_f="14338">Furutani </offsets><italic><offsets xml_i="20181" xml_f="20186" txt_i="14338" txt_f="14343">et al</offsets></italic><offsets xml_i="20195" xml_f="20201" txt_i="14343" txt_f="14349">, 2010</offsets></xref><offsets xml_i="20208" xml_f="20456" txt_i="14349" txt_f="14597">). Other inherent action of lidocaine would be the phosphorylation attenuation of p38 mitogen-activated protein kinase in the activated microglia of spinal cord, reversing established tactile allodynia in chronic constriction injury model of rats (</offsets><xref ref-type="bibr" rid="bib13"><offsets xml_i="20490" xml_f="20493" txt_i="14597" txt_f="14600">Gu </offsets><italic><offsets xml_i="20501" xml_f="20506" txt_i="14600" txt_f="14605">et al</offsets></italic><offsets xml_i="20515" xml_f="20521" txt_i="14605" txt_f="14611">, 2008</offsets></xref><offsets xml_i="20528" xml_f="20991" txt_i="14611" txt_f="15074">). In our study, the association of low-dose lidocaine and escalating doses of epidural methadone was evaluated. The results demonstrated that neither the epidural dose of 40‚Äâmg lidocaine alone nor combined with 2.5‚Äâmg methadone were effective for improving cancer pain. Lidocaine has been previously demonstrated to produce analgesia for somatic and visceral pain at the spinal level, which was synergistic with a non-NMDA glutamate receptor antagonist in rats (</offsets><xref ref-type="bibr" rid="bib17"><offsets xml_i="21025" xml_f="21034" txt_i="15074" txt_f="15083">Imamashi </offsets><italic><offsets xml_i="21042" xml_f="21047" txt_i="15083" txt_f="15088">et al</offsets></italic><offsets xml_i="21056" xml_f="21062" txt_i="15088" txt_f="15094">, 1999</offsets></xref><offsets xml_i="21069" xml_f="21315" txt_i="15094" txt_f="15340">). Isobolographic analysis also revealed that the epidural opioid morphine and lidocaine interacted synergistically in both somatic and visceral nociception tests, and naloxone antagonised the antinociceptive effects produced by the combination (</offsets><xref ref-type="bibr" rid="bib20"><offsets xml_i="21349" xml_f="21356" txt_i="15340" txt_f="15347">Kaneko </offsets><italic><offsets xml_i="21364" xml_f="21369" txt_i="15347" txt_f="15352">et al</offsets></italic><offsets xml_i="21378" xml_f="21384" txt_i="15352" txt_f="15358">, 1994</offsets></xref><offsets xml_i="21391" xml_f="21612" txt_i="15358" txt_f="15579">). Whether local anaesthetics would act as anti-inflammatory and in micro-molar concentrations would inhibit extracellular oxygen release in spinal microglia; as described elsewhere for neutrophil priming and activation (</offsets><xref ref-type="bibr" rid="bib33"><offsets xml_i="21646" xml_f="21653" txt_i="15579" txt_f="15586">Ploppa </offsets><italic><offsets xml_i="21661" xml_f="21666" txt_i="15586" txt_f="15591">et al</offsets></italic><offsets xml_i="21675" xml_f="21681" txt_i="15591" txt_f="15597">, 2010</offsets></xref><offsets xml_i="21688" xml_f="21702" txt_i="15597" txt_f="15611">), is unknown.</offsets></p><p><offsets xml_i="21709" xml_f="22038" txt_i="15612" txt_f="15941">A different combination of drugs was the DG, which patients received both epidural dexamethasone and lidocaine. Dexamethasone profits may be secondary to glucocorticoid receptor activation, in turn rapidly suppressing basal and stress-induced hypothalamus‚Äìpituitary‚Äìadrenal activity partly through a central mechanism of action (</offsets><xref ref-type="bibr" rid="bib1"><offsets xml_i="22071" xml_f="22079" txt_i="15941" txt_f="15949">Andrews </offsets><italic><offsets xml_i="22087" xml_f="22092" txt_i="15949" txt_f="15954">et al</offsets></italic><offsets xml_i="22101" xml_f="22107" txt_i="15954" txt_f="15960">, 2012</offsets></xref><offsets xml_i="22114" xml_f="22336" txt_i="15960" txt_f="16182">). At the level of the paraventricular nucleous, dexamethasone rapidly reduced hypothalamus‚Äìpituitary‚Äìadrenal axis activation in a non-genomic, membrane-associated manner, involving cannabinoid receptor type 1 signalling (</offsets><xref ref-type="bibr" rid="bib8"><offsets xml_i="22369" xml_f="22377" txt_i="16182" txt_f="16190">Evanson </offsets><italic><offsets xml_i="22385" xml_f="22390" txt_i="16190" txt_f="16195">et al</offsets></italic><offsets xml_i="22399" xml_f="22405" txt_i="16195" txt_f="16201">, 2010</offsets></xref><offsets xml_i="22412" xml_f="22518" txt_i="16201" txt_f="16307">). Apart, corticosteroid was demonstrated to effectively reduce myelin changes accompanying brain oedema (</offsets><xref ref-type="bibr" rid="bib21"><offsets xml_i="22552" xml_f="22559" txt_i="16307" txt_f="16314">Kozler </offsets><italic><offsets xml_i="22567" xml_f="22572" txt_i="16314" txt_f="16319">et al</offsets></italic><offsets xml_i="22581" xml_f="22587" txt_i="16319" txt_f="16325">, 2011</offsets></xref><offsets xml_i="22594" xml_f="22977" txt_i="16325" txt_f="16708">) that would benefit patients suffering from oedema secondary to spinal metastasis or to hidroeletrolytic disturbances. In addition, high levels of glucocorticoid receptor and mineralocorticoid receptor are colocalized in the substantia gelatinosa where pain pathways appear to be under a strong regulation of these receptors, and nociception was attenuated by spinal dexamethasone (</offsets><xref ref-type="bibr" rid="bib12"><offsets xml_i="23011" xml_f="23014" txt_i="16708" txt_f="16711">Gu </offsets><italic><offsets xml_i="23022" xml_f="23027" txt_i="16711" txt_f="16716">et al</offsets></italic><offsets xml_i="23036" xml_f="23042" txt_i="16716" txt_f="16722">, 2011</offsets></xref><offsets xml_i="23049" xml_f="23253" txt_i="16722" txt_f="16926">). Other possible speculated mechanism of action for the epidural dexamethasone could be the attenuation of the ciclooxigenase-2-dependent production of prostanoids, mainly vasoactive prostaglandin-E(2) (</offsets><xref ref-type="bibr" rid="bib9"><offsets xml_i="23286" xml_f="23298" txt_i="16926" txt_f="16938">Font-Nieves </offsets><italic><offsets xml_i="23306" xml_f="23311" txt_i="16938" txt_f="16943">et al</offsets></italic><offsets xml_i="23320" xml_f="23326" txt_i="16943" txt_f="16949">, 2012</offsets></xref><offsets xml_i="23333" xml_f="23647" txt_i="16949" txt_f="17263">) from the astrocytes that surround the synapse between the first- and second-order neuron in the spinal cord. Apart from spinal mechanism of action, dexamethasone could also decrease astrocyte-to-neuron communication in the hypothalamus through inhibition of production of the gliotransmitter prostaglandin-E(2) (</offsets><xref ref-type="bibr" rid="bib5"><offsets xml_i="23680" xml_f="23691" txt_i="17263" txt_f="17274">Clasadonte </offsets><italic><offsets xml_i="23699" xml_f="23704" txt_i="17274" txt_f="17279">et al</offsets></italic><offsets xml_i="23713" xml_f="23719" txt_i="17279" txt_f="17285">, 2011</offsets></xref><offsets xml_i="23726" xml_f="23940" txt_i="17285" txt_f="17499">). Dexamethasone also prevented lidocaine-induced neurotoxicity in tumour cells through prevention of mitochondrial potential decline and also increased levels of threonine-serine protein kinase B phosphorylation (</offsets><xref ref-type="bibr" rid="bib26"><offsets xml_i="23974" xml_f="23977" txt_i="17499" txt_f="17502">Ma </offsets><italic><offsets xml_i="23985" xml_f="23990" txt_i="17502" txt_f="17507">et al</offsets></italic><offsets xml_i="23999" xml_f="24005" txt_i="17507" txt_f="17513">, 2010</offsets></xref><offsets xml_i="24012" xml_f="24351" txt_i="17513" txt_f="17852">). Finally, the final combination evaluated in this clinical setting was epidural lidocaine plus methadone plus the glucocorticoid dexamethasone. Co-administration of dexamethasone and glutamate receptor antagonists (such as spinal methadone and lidocaine) for treating nociception have been previously described in rats in the periphery (</offsets><xref ref-type="bibr" rid="bib23"><offsets xml_i="24385" xml_f="24401" txt_i="17852" txt_f="17868">Lam and Ng, 2012</offsets></xref><offsets xml_i="24408" xml_f="24425" txt_i="17868" txt_f="17885">) and centrally (</offsets><xref ref-type="bibr" rid="bib3"><offsets xml_i="24458" xml_f="24469" txt_i="17885" txt_f="17896">Bertorelli </offsets><italic><offsets xml_i="24477" xml_f="24482" txt_i="17896" txt_f="17901">et al</offsets></italic><offsets xml_i="24491" xml_f="24497" txt_i="17901" txt_f="17907">, 1998</offsets></xref><offsets xml_i="24504" xml_f="24636" txt_i="17907" txt_f="18039">). In accordance, our results revealed around 14 days of pain relief from a single bolus dose of the combination of the three drugs.</offsets></p><p><offsets xml_i="24643" xml_f="25631" txt_i="18040" txt_f="19028">Additional benefits in patients who received epidural dexamethasone included decreased incidence of daily somnolence, decrease fatigue and appetite improvement after both dexamethasone and 7.5‚Äâmg methadone during the first 14 days evaluation, while only fatigue improved for DG at day-7 and -14. Probably somnolence and appetite improvement were not enriched in this group due to the higher oral daily dose of morphine consumption they displayed. The gradual increase in morphine consumption to all groups after day-15 was probably reflection of the particularity of the study population (high incidence of metastasis) and of the study drug protocol, where only morphine was allowed as rescue analgesic. Another point to be considered is that cancer patients suffer from stress of the disease knowledge, anxiety and pain that may result in dysfunction of glutamatergic neurotransmission, including effects on glutamate release, glutamate receptors and glutamate clearance and metabolism (</offsets><xref ref-type="bibr" rid="bib34"><offsets xml_i="25665" xml_f="25672" txt_i="19028" txt_f="19035">Popoli </offsets><italic><offsets xml_i="25680" xml_f="25685" txt_i="19035" txt_f="19040">et al</offsets></italic><offsets xml_i="25694" xml_f="25700" txt_i="19040" txt_f="19046">, 2011</offsets></xref><offsets xml_i="25707" xml_f="25916" txt_i="19046" txt_f="19255">). A positive effect of the combination of lidocaine, methadone and dexamethasone in this population could be at least partly due to their neuroprotective effect on the dorsal root ganglion and Schawnn cells (</offsets><xref ref-type="bibr" rid="bib40"><offsets xml_i="25950" xml_f="25970" txt_i="19255" txt_f="19275">Zhu and Glaser, 2008</offsets></xref><offsets xml_i="25977" xml_f="25979" txt_i="19275" txt_f="19277">; </offsets><xref ref-type="bibr" rid="bib26"><offsets xml_i="26013" xml_f="26016" txt_i="19277" txt_f="19280">Ma </offsets><italic><offsets xml_i="26024" xml_f="26029" txt_i="19280" txt_f="19285">et al</offsets></italic><offsets xml_i="26038" xml_f="26044" txt_i="19285" txt_f="19291">, 2010</offsets></xref><offsets xml_i="26051" xml_f="26204" txt_i="19291" txt_f="19444">), as antagonists of NMDA receptor combined with dexamethasone have been described to reduce the production of tumour necrosis factor level in the brain.</offsets></p><p><offsets xml_i="26211" xml_f="26349" txt_i="19445" txt_f="19583">In summary, dexamethasone would enhance methadone analgesia partly through: (1) overwhelming the hypothalamus‚Äìpituitary‚Äìadrenal activity (</offsets><xref ref-type="bibr" rid="bib1"><offsets xml_i="26382" xml_f="26390" txt_i="19583" txt_f="19591">Andrews </offsets><italic><offsets xml_i="26398" xml_f="26403" txt_i="19591" txt_f="19596">et al</offsets></italic><offsets xml_i="26412" xml_f="26418" txt_i="19596" txt_f="19602">, 2012</offsets></xref><offsets xml_i="26425" xml_f="26526" txt_i="19602" txt_f="19703">), that would be further enhanced by ciclooxigenase-2 attenuation at astrocytes in the hypothalamus (</offsets><xref ref-type="bibr" rid="bib5"><offsets xml_i="26559" xml_f="26570" txt_i="19703" txt_f="19714">Clasadonte </offsets><italic><offsets xml_i="26578" xml_f="26583" txt_i="19714" txt_f="19719">et al</offsets></italic><offsets xml_i="26592" xml_f="26598" txt_i="19719" txt_f="19725">, 2011</offsets></xref><offsets xml_i="26605" xml_f="26691" txt_i="19725" txt_f="19811">); (2) inhibition of glutamate release at the dorsal raphe serotonergic 5-HT neurons (</offsets><xref ref-type="bibr" rid="bib8"><offsets xml_i="26724" xml_f="26732" txt_i="19811" txt_f="19819">Evanson </offsets><italic><offsets xml_i="26740" xml_f="26745" txt_i="19819" txt_f="19824">et al</offsets></italic><offsets xml_i="26754" xml_f="26760" txt_i="19824" txt_f="19830">, 2010</offsets></xref><offsets xml_i="26767" xml_f="26769" txt_i="19830" txt_f="19832">; </offsets><xref ref-type="bibr" rid="bib39"><offsets xml_i="26803" xml_f="26808" txt_i="19832" txt_f="19837">Wang </offsets><italic><offsets xml_i="26816" xml_f="26821" txt_i="19837" txt_f="19842">et al</offsets></italic><offsets xml_i="26830" xml_f="26836" txt_i="19842" txt_f="19848">, 2012</offsets></xref><offsets xml_i="26843" xml_f="26884" txt_i="19848" txt_f="19889">); and (3) ciclooxigenase-2 attenuation (</offsets><xref ref-type="bibr" rid="bib9"><offsets xml_i="26917" xml_f="26929" txt_i="19889" txt_f="19901">Font-Nievis </offsets><italic><offsets xml_i="26937" xml_f="26942" txt_i="19901" txt_f="19906">et al</offsets></italic><offsets xml_i="26951" xml_f="26957" txt_i="19906" txt_f="19912">, 2012</offsets></xref><offsets xml_i="26964" xml_f="27000" txt_i="19912" txt_f="19948">) from the astrocytes at the spine (</offsets><xref ref-type="bibr" rid="bib5"><offsets xml_i="27033" xml_f="27044" txt_i="19948" txt_f="19959">Clasadonte </offsets><italic><offsets xml_i="27052" xml_f="27057" txt_i="19959" txt_f="19964">et al</offsets></italic><offsets xml_i="27066" xml_f="27072" txt_i="19964" txt_f="19970">, 2011</offsets></xref><offsets xml_i="27079" xml_f="27162" txt_i="19970" txt_f="20053">). In addition, because mental fatigue is related to activation of NMDA receptors (</offsets><xref ref-type="bibr" rid="bib28"><offsets xml_i="27196" xml_f="27205" txt_i="20053" txt_f="20062">Morimoto </offsets><italic><offsets xml_i="27213" xml_f="27218" txt_i="20062" txt_f="20067">et al</offsets></italic><offsets xml_i="27227" xml_f="27233" txt_i="20067" txt_f="20073">, 2012</offsets></xref><offsets xml_i="27240" xml_f="27421" txt_i="20073" txt_f="20254">), it would be improved by NMDA antagonist such as methadone. Another detail that deserves attention is that cannabinoids have been described to improve fatigue in cancer patients (</offsets><xref ref-type="bibr" rid="bib19"><offsets xml_i="27455" xml_f="27463" txt_i="20254" txt_f="20262">Johnson </offsets><italic><offsets xml_i="27471" xml_f="27476" txt_i="20262" txt_f="20267">et al</offsets></italic><offsets xml_i="27485" xml_f="27491" txt_i="20267" txt_f="20273">, 2012</offsets></xref><offsets xml_i="27498" xml_f="27649" txt_i="20273" txt_f="20424">) and dexamethasone is known to bind at glucocorticoid receptors, activate G-protein coupled receptors and be signalled by endocannabinoid messengers (</offsets><xref ref-type="bibr" rid="bib28"><offsets xml_i="27683" xml_f="27692" txt_i="20424" txt_f="20433">Morimoto </offsets><italic><offsets xml_i="27700" xml_f="27705" txt_i="20433" txt_f="20438">et al</offsets></italic><offsets xml_i="27714" xml_f="27720" txt_i="20438" txt_f="20444">, 2012</offsets></xref><offsets xml_i="27727" xml_f="27811" txt_i="20444" txt_f="20528">) and could therefore diminish fatigue by acting indirectly as adjuvant cannabinoid.</offsets></p><p><offsets xml_i="27818" xml_f="28162" txt_i="20529" txt_f="20873">Other adverse effects described in the literature, however, not mentioned by our population was pruritus and urinary retention. The incidence of pruritus after epidural methadone was significantly slighter compared with morphine. Epidural morphine was also associated with a significantly greater incidence of urinary retention than methadone (</offsets><xref ref-type="bibr" rid="bib11"><offsets xml_i="28196" xml_f="28216" txt_i="20873" txt_f="20893">Gedney and Liu, 1998</offsets></xref><offsets xml_i="28223" xml_f="28225" txt_i="20893" txt_f="20895">).</offsets></p><p><offsets xml_i="28232" xml_f="28524" txt_i="20896" txt_f="21188">In conclusion, epidural 2.5‚Äì7.5‚Äâmg methadone combined to low-dose lidocaine (40‚Äâmg) resulted in dose-dependent analgesia in cancer pain patients. This analgesic effect was further enhanced by 10‚Äâmg epidural dexamethasone, associated with improvement of fatigue, daily somnolence and appetite.</offsets></p></sec></body><back><ack><p>We thank Cristalia for the donation of conservative-free racemic Methadone ampoules. The cost of the study was supported by the Center for Pain management-HC-FMRP-USP.</p></ack><fn-group><fn><p>This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.</p></fn></fn-group><ref-list><ref id="bib1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>MH</given-names></name><name><surname>Wood</surname><given-names>SA</given-names></name><name><surname>Windle</surname><given-names>RJ</given-names></name><name><surname>Lightman</surname><given-names>SL</given-names></name><name><surname>Ingram</surname><given-names>CD</given-names></name></person-group><year>2012</year><article-title>Acute glucocorticoid administration rapidly suppresses basal and stress-induced hypothalamus-pituitary-adrenal axis activity</article-title><source>Endocrinology</source><volume>153</volume><fpage>200</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">22087024</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anghelescu</surname><given-names>DL</given-names></name><name><surname>Faughnan</surname><given-names>LG</given-names></name><name><surname>Hankins</surname><given-names>GM</given-names></name><name><surname>Ward</surname><given-names>DA</given-names></name><name><surname>Oakes</surname><given-names>LL</given-names></name></person-group><year>2011</year><article-title>Methadone use in children and young adults at a cancer center: a retrospective study</article-title><source>J Opioid Manag</source><volume>7</volume><fpage>353</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">22165034</pub-id></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertorelli</surname><given-names>R</given-names></name><name><surname>Adami</surname><given-names>M</given-names></name><name><surname>Di Santo</surname><given-names>E</given-names></name><name><surname>Ghezzi</surname><given-names>P</given-names></name></person-group><year>1998</year><article-title>MK 801 and dexamethasone reduce both tumor necrosis factor levels and infarct volume after focal cerebral ischemia in the rat brain</article-title><source>Neurosci Lett</source><volume>246</volume><fpage>41</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">9622203</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christo</surname><given-names>PJ</given-names></name><name><surname>Mazloomdoost</surname><given-names>D</given-names></name></person-group><year>2008</year><article-title>Interventional pain treatments for cancer pain</article-title><source>Ann NY Acad Sci</source><volume>1138</volume><fpage>299</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">18837908</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clasadonte</surname><given-names>J</given-names></name><name><surname>Poulain</surname><given-names>P</given-names></name><name><surname>Hanchate</surname><given-names>NK</given-names></name><name><surname>Corfas</surname><given-names>G</given-names></name><name><surname>Ojeda</surname><given-names>SR</given-names></name><name><surname>Prevot</surname><given-names>V</given-names></name></person-group><year>2011</year><article-title>Prostaglandin E2 release from astrocytes triggers gonadotropin-releasing hormone (GnRH) neuron firing via EP2 receptor activation</article-title><source>Proc Natl Acad Sci USA</source><volume>108</volume><fpage>16104</fpage><lpage>16109</lpage><pub-id pub-id-type="pmid">21896757</pub-id></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dexter</surname><given-names>F</given-names></name><name><surname>Chestnut</surname><given-names>DH</given-names></name></person-group><year>1995</year><article-title>Analysis of statistical tests to compare visual analog scale measurements among groups</article-title><source>Anesthesiology</source><volume>82</volume><fpage>896</fpage><lpage>902</lpage><pub-id pub-id-type="pmid">7717561</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>H</given-names></name><name><surname>Fan</surname><given-names>YH</given-names></name><name><surname>Wang</surname><given-names>YY</given-names></name><name><surname>Wang</surname><given-names>WT</given-names></name><name><surname>Hu</surname><given-names>SJ</given-names></name></person-group><year>2008</year><article-title>Lidocaine suppresses subthreshold oscillations by inhibiting persistent Na(+) current in injured dorsal root ganglion neurons</article-title><source>Physiol Res</source><volume>57</volume><fpage>639</fpage><lpage>645</lpage><pub-id pub-id-type="pmid">17705679</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evanson</surname><given-names>NK</given-names></name><name><surname>Tasker</surname><given-names>JG</given-names></name><name><surname>Hill</surname><given-names>MN</given-names></name><name><surname>Hillard</surname><given-names>CJ</given-names></name><name><surname>Herman</surname><given-names>JP</given-names></name></person-group><year>2010</year><article-title>Fast feedback inhibition of the HPA axis by glucocorticoids Is mediated by endocannabinoid signaling</article-title><source>Endocrinology</source><volume>151</volume><fpage>4811</fpage><lpage>4819</lpage><pub-id pub-id-type="pmid">20702575</pub-id></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Font-Nieves</surname><given-names>M</given-names></name><name><surname>Sans-Fons</surname><given-names>MG</given-names></name><name><surname>Gorina</surname><given-names>R</given-names></name><name><surname>Bonfill-Teixidor</surname><given-names>E</given-names></name><name><surname>Salas-P√©rdomo</surname><given-names>A</given-names></name><name><surname>M√°rquez-Kisinousky</surname><given-names>L</given-names></name><name><surname>Santalucia</surname><given-names>T</given-names></name><name><surname>Planas</surname><given-names>AM</given-names></name></person-group><year>2012</year><article-title>Induction of COX-2 enzyme and down-regulation of COX-1 expression by lipopolysaccharide (LPS) control prostaglandin E2 production in astrocytes</article-title><source>J Biol Chem</source><volume>287</volume><fpage>6454</fpage><lpage>6468</lpage><pub-id pub-id-type="pmid">22219191</pub-id></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furutani</surname><given-names>K</given-names></name><name><surname>Ikoma</surname><given-names>M</given-names></name><name><surname>Ishii</surname><given-names>H</given-names></name><name><surname>Baba</surname><given-names>H</given-names></name><name><surname>Kohno</surname><given-names>T</given-names></name></person-group><year>2010</year><article-title>Bupivacaine inhibits glutamatergic transmission in spinal dorsal horn neurons</article-title><source>Anesthesiology</source><volume>112</volume><fpage>138</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">20032703</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gedney</surname><given-names>JA</given-names></name><name><surname>Liu</surname><given-names>EH</given-names></name></person-group><year>1998</year><article-title>Side-effects of epidural infusions of opioid bupivacaine mixtures</article-title><source>Anaesthesia</source><volume>53</volume><fpage>1148</fpage><lpage>1155</lpage><pub-id pub-id-type="pmid">10193215</pub-id></mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Peng</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name></person-group><year>2011</year><article-title>The respective and interaction effects of spinal GRs and MRs on radicular pain induced by chronic compression of the dorsal root ganglion in the rat</article-title><source>Brain Res</source><volume>1396</volume><fpage>88</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">21550593</pub-id></mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>YW</given-names></name><name><surname>Su</surname><given-names>DS</given-names></name><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>XR</given-names></name></person-group><year>2008</year><article-title>Attenuating phosphorylation of p38 MAPK in the activated microglia: a new mechanism for intrathecal lidocaine reversing tactile allodynia following chronic constriction injury in rats</article-title><source>Neurosci Lett</source><volume>431</volume><fpage>129</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">18191894</pub-id></mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hattori</surname><given-names>S</given-names></name><name><surname>Sano</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Yokota</surname><given-names>M</given-names></name></person-group><year>2009</year><article-title>Intrathecal morphine treatment in advanced cancer pain patients</article-title><source>Masui</source><volume>58</volume><fpage>1384</fpage><lpage>1392</lpage><pub-id pub-id-type="pmid">19928505</pub-id></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>L</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Ou</surname><given-names>C</given-names></name><name><surname>McFadden</surname><given-names>W</given-names></name><name><surname>van Rijn</surname><given-names>RM</given-names></name><name><surname>Whistler</surname><given-names>JL</given-names></name></person-group><year>2010</year><article-title>Methadone antinociception is dependent on peripheral opioid receptors</article-title><source>J Pain</source><volume>10</volume><fpage>369</fpage><lpage>379</lpage><pub-id pub-id-type="pmid">19327642</pub-id></mixed-citation></ref><ref id="bib16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutchinson</surname><given-names>MR</given-names></name><name><surname>Lewis</surname><given-names>SS</given-names></name><name><surname>Coats</surname><given-names>BD</given-names></name><name><surname>Rezvani</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wieseler</surname><given-names>JL</given-names></name><name><surname>Somogyi</surname><given-names>AA</given-names></name><name><surname>Yin</surname><given-names>H</given-names></name><name><surname>Maier</surname><given-names>SF</given-names></name><name><surname>Rice</surname><given-names>KC</given-names></name><name><surname>Watkins</surname><given-names>LR</given-names></name></person-group><year>2010</year><article-title>Possible involvement of toll-like receptor 4/myeloid differentiation factor-2 activity of opioid inactive isomers causes spinal proinflammation and related behavioral consequences</article-title><source>Neuroscience</source><volume>167</volume><fpage>880</fpage><lpage>893</lpage><pub-id pub-id-type="pmid">20178837</pub-id></mixed-citation></ref><ref id="bib17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imamachi</surname><given-names>N</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Hara</surname><given-names>K</given-names></name><name><surname>Sakura</surname><given-names>S</given-names></name><name><surname>Kosaka</surname><given-names>Y</given-names></name></person-group><year>1999</year><article-title>The non-NMDA glutamate receptor antagonist CNQX augments lidocaine antinociception through a spinal action in rats</article-title><source>Anesth Analg</source><volume>89</volume><fpage>416</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">10439758</pub-id></mixed-citation></ref><ref id="bib18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inturrisi</surname><given-names>CE</given-names></name></person-group><year>2005</year><article-title>Pharmacology of methadone and its isomers</article-title><source>Minerva Anestesiol</source><volume>71</volume><fpage>435</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">16012416</pub-id></mixed-citation></ref><ref id="bib19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>JR</given-names></name><name><surname>Lossignol</surname><given-names>D</given-names></name><name><surname>Burnell-Nugent</surname><given-names>M</given-names></name><name><surname>Fallon</surname><given-names>MT</given-names></name></person-group><year>2012</year><article-title>An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics</article-title><source>J Pain Symptom Manage</source><volume>S0885-3924</volume><supplement>(12</supplement><fpage>00439</fpage><lpage>3</lpage></mixed-citation></ref><ref id="bib20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaneko</surname><given-names>M</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Kirihara</surname><given-names>Y</given-names></name><name><surname>Collins</surname><given-names>JG</given-names></name><name><surname>Kosaka</surname><given-names>Y</given-names></name></person-group><year>1994</year><article-title>Synergistic antinociceptive interaction after epidural coadministration of morphine and lidocaine in rats</article-title><source>Anesthesiology</source><volume>80</volume><fpage>137</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">8291703</pub-id></mixed-citation></ref><ref id="bib21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kozler</surname><given-names>P</given-names></name><name><surname>Riljak</surname><given-names>V</given-names></name><name><surname>Pokorn√Ω</surname><given-names>J</given-names></name></person-group><year>2011</year><article-title>Methylprednisolone reduces axonal impairment in the experimental model of brain oedema</article-title><source>Neuro Endocrinol Lett</source><volume>32</volume><fpage>831</fpage><lpage>835</lpage><pub-id pub-id-type="pmid">22286794</pub-id></mixed-citation></ref><ref id="bib22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurita</surname><given-names>GP</given-names></name><name><surname>Kaasa</surname><given-names>S</given-names></name><name><surname>Sj√∏gren</surname><given-names>P</given-names></name><collab>European Palliative Care Research Collaborative (EPCRC)</collab></person-group><year>2011</year><article-title>Spinal opioids in adult patients with cancer pain: a systematic review: a European Palliative Care Research Collaborative (EPCRC) opioid guidelines project</article-title><source>Palliat Med</source><volume>25</volume><fpage>560</fpage><lpage>577</lpage><pub-id pub-id-type="pmid">21708860</pub-id></mixed-citation></ref><ref id="bib23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>FF</given-names></name><name><surname>Ng</surname><given-names>ES</given-names></name></person-group><year>2012</year><article-title>Substance P and glutamate receptor antagonists improve the anti-arthritic actions of dexamethasone in rats</article-title><source>Br J Pharmacol</source><volume>159</volume><fpage>958</fpage><lpage>969</lpage><pub-id pub-id-type="pmid">20128799</pub-id></mixed-citation></ref><ref id="bib24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leppert</surname><given-names>W</given-names></name></person-group><year>2009</year><article-title>The role of methadone in cancer pain treatment‚Äìa review</article-title><source>Int J Clin Pract</source><volume>63</volume><fpage>1095</fpage><lpage>1109</lpage><pub-id pub-id-type="pmid">19570126</pub-id></mixed-citation></ref><ref id="bib25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leppert</surname><given-names>W</given-names></name><name><surname>Buss</surname><given-names>T</given-names></name></person-group><year>2012</year><article-title>The role of corticosteroids in the treatment of pain in cancer patients</article-title><source>Curr Pain Headache Rep</source><volume>16</volume><fpage>307</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">22644902</pub-id></mixed-citation></ref><ref id="bib26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Ding</surname><given-names>Z</given-names></name></person-group><year>2010</year><article-title>Dexamethasone attenuated bupivacaine-induced neuron injury <italic>in vitro</italic> through a threonine-serine protein kinase B-dependent mechanism</article-title><source>Neuroscience</source><volume>167</volume><fpage>329</fpage><lpage>342</lpage><pub-id pub-id-type="pmid">20038443</pub-id></mixed-citation></ref><ref id="bib27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mercadante</surname><given-names>S</given-names></name></person-group><year>2012</year><article-title>Switching methadone: a 10-year experience of 345 patients in an acute palliative care unit</article-title><source>Pain Med</source><volume>13</volume><fpage>399</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">22360828</pub-id></mixed-citation></ref><ref id="bib28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morimoto</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Adachi</surname><given-names>K</given-names></name></person-group><year>2012</year><article-title>Effects of memantine, an N-methyl-D-aspartate receptor antagonist, on fatigue and neuronal brain damage in a rat model of combined (physical and mental) fatigue</article-title><source>Biol Pharm Bull</source><volume>35</volume><fpage>481</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">22466550</pub-id></mixed-citation></ref><ref id="bib29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muth-Selbach</surname><given-names>U</given-names></name><name><surname>Hermanns</surname><given-names>H</given-names></name><name><surname>Stegmann</surname><given-names>JU</given-names></name><name><surname>Kollosche</surname><given-names>K</given-names></name><name><surname>Freynhagen</surname><given-names>R</given-names></name><name><surname>Bauer</surname><given-names>I</given-names></name><name><surname>Lipfert</surname><given-names>P</given-names></name></person-group><year>2009</year><article-title>Antinociceptive effects of systemic lidocaine: involvement of the spinal glycinergic system</article-title><source>Eur J Pharmacol</source><volume>613</volume><fpage>68</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">19394327</pub-id></mixed-citation></ref><ref id="bib30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olbrich</surname><given-names>VH</given-names></name><name><surname>Mosing</surname><given-names>M</given-names></name></person-group><year>2003</year><article-title>A comparison of the analgesic effects of caudal epidural methadone and lidocaine in the horse</article-title><source>Vet Anaesth Analg</source><volume>30</volume><fpage>156</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">14498847</pub-id></mixed-citation></ref><ref id="bib31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olschewski</surname><given-names>A</given-names></name><name><surname>Schnoebel-Ehehalt</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>B</given-names></name><name><surname>Br√§u</surname><given-names>ME</given-names></name><name><surname>Wolff</surname><given-names>M</given-names></name></person-group><year>2009</year><article-title>Mexiletine and lidocaine suppress the excitability of dorsal horn neurons</article-title><source>Anesth Analg</source><volume>109</volume><fpage>258</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">19535719</pub-id></mixed-citation></ref><ref id="bib32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parramon</surname><given-names>F</given-names></name><name><surname>Garc√≠a</surname><given-names>Ch</given-names></name><name><surname>Gamb√∫s</surname><given-names>P</given-names></name><name><surname>Vilaplana</surname><given-names>J</given-names></name><name><surname>Aragon√©s</surname><given-names>N</given-names></name><name><surname>Villalonga</surname><given-names>A</given-names></name></person-group><year>2003</year><article-title>Postoperative patient-controlled analgesia is more effective with epidural methadone than with intravenous methadone in thoracic surgery</article-title><source>Rev Esp Anestesiol Reanim</source><volume>50</volume><fpage>326</fpage><lpage>331</lpage><pub-id pub-id-type="pmid">14552104</pub-id></mixed-citation></ref><ref id="bib33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ploppa</surname><given-names>A</given-names></name><name><surname>Kiefer</surname><given-names>RT</given-names></name><name><surname>Haverstick</surname><given-names>DM</given-names></name><name><surname>Groves</surname><given-names>DS</given-names></name><name><surname>Unertl</surname><given-names>KE</given-names></name><name><surname>Durieux</surname><given-names>ME</given-names></name></person-group><year>2010</year><article-title>Local anesthetic effects on human neutrophil priming and activation</article-title><source>Reg Anesth Pain Med</source><volume>35</volume><fpage>45</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">20048657</pub-id></mixed-citation></ref><ref id="bib34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popoli</surname><given-names>M</given-names></name><name><surname>Yan</surname><given-names>Z</given-names></name><name><surname>McEwen</surname><given-names>BS</given-names></name><name><surname>Sanacora</surname><given-names>G</given-names></name></person-group><year>2011</year><article-title>The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission</article-title><source>Nat Rev Neurosci</source><volume>13</volume><fpage>22</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">22127301</pub-id></mixed-citation></ref><ref id="bib35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prieto-Alvarez</surname><given-names>P</given-names></name><name><surname>Tello-Galindo</surname><given-names>I</given-names></name><name><surname>Cuenca-Pe√±a</surname><given-names>J</given-names></name><name><surname>Rull-Bartomeu</surname><given-names>M</given-names></name><name><surname>Gomar-Sancho</surname><given-names>C</given-names></name></person-group><year>2002</year><article-title>Continuous epidural infusion of racemic methadone results in effective postoperative analgesia and low plasma concentrations</article-title><source>Can J Anaesth</source><volume>49</volume><fpage>25</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">11782325</pub-id></mixed-citation></ref><ref id="bib36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>P√©rez</surname><given-names>J</given-names></name><name><surname>de Santos</surname><given-names>P</given-names></name><name><surname>Plaza</surname><given-names>A</given-names></name><name><surname>Mercadal</surname><given-names>J</given-names></name></person-group><year>2010</year><article-title>Adjuvant methadone or fentanyl in spinal anesthesia with bupivacaine: a randomized, double-blind, placebo-controlled trial</article-title><source>Rev Esp Anestesiol Reanim</source><volume>57</volume><fpage>546</fpage><lpage>552</lpage><pub-id pub-id-type="pmid">21155334</pub-id></mixed-citation></ref><ref id="bib37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shir</surname><given-names>Y</given-names></name><name><surname>Shapira</surname><given-names>SS</given-names></name><name><surname>Shenkman</surname><given-names>Z</given-names></name><name><surname>Kaufman</surname><given-names>B</given-names></name><name><surname>Magora</surname><given-names>F</given-names></name></person-group><year>1991</year><article-title>Continuous epidural methadone treatment for cancer pain</article-title><source>Clin J Pain</source><volume>7</volume><fpage>339</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">1809448</pub-id></mixed-citation></ref><ref id="bib38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sotgiu</surname><given-names>ML</given-names></name><name><surname>Valente</surname><given-names>M</given-names></name><name><surname>Storchi</surname><given-names>R</given-names></name><name><surname>Caramenti</surname><given-names>G</given-names></name><name><surname>Biella</surname><given-names>GE</given-names></name><collab>Cooperative</collab></person-group><year>2009</year><article-title>N-methyl-D-aspartate (NMDA) receptor antagonism and mu-opioid receptor agonism mediate the methadone inhibition of the spinal neuron pain-related hyperactivity in a rat model of neuropathic pain</article-title><source>Pharmacol Res</source><volume>60</volume><fpage>284</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">19717013</pub-id></mixed-citation></ref><ref id="bib39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>RY</given-names></name><name><surname>Haj-Dahmane</surname><given-names>S</given-names></name></person-group><year>2012</year><article-title>Endocannabinoids mediate the glucocorticoid-induced inhibition of excitatory synaptic transmission to dorsal raphe serotonin neurons</article-title><source>J Physiol</source><volume>590</volume><supplement>(Pt 22</supplement><fpage>5795</fpage><lpage>808</lpage><pub-id pub-id-type="pmid">22946098</pub-id></mixed-citation></ref><ref id="bib40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>TS</given-names></name><name><surname>Glaser</surname><given-names>M</given-names></name></person-group><year>2008</year><article-title>Neuroprotection and enhancement of remyelination by estradiol and dexamethasone in cocultures of rat DRG neurons and Schwann cells</article-title><source>Brain Res</source><volume>1206</volume><fpage>20</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">18367155</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig id="fig1"><label>Figure 1</label><caption><p><bold>Daily consumption of oral morphine in the groups.</bold> CG=control group; 2.5MetG=2.5‚Äâmg methadone group; 5MetG=5‚Äâmg methadone group; 7.5MetG=7.5‚Äâmg methadone group; 7.5MetDG=7.5‚Äâmg methadone-dexamethasone group. Day-1=the CG, DG and 2.5MetG kept the daily oral consumption of 80‚Äì90‚Äâmg morphine (<italic>P</italic>&gt;0.05). CG=DG=2.5MetG during all the 21-day evaluation regarding oral daily morphine consumption (<italic>P</italic>&gt;0.05). Patients started the evaluation on day-1 taking 80‚Äì90‚Äâmg oral morphine, which was gradually increasing for CG, DG and 2.5MetG until day-21 (150‚Äì170‚Äâmg morphine) (daily evaluation-<italic>P</italic>&gt;0.05) 5MetG=from day-1 to day-3, the daily intake of oral morphine was: 5MetG=7.5MetG=7.5MetDG (<italic>P</italic>&gt;0.05) &lt; CG=DG=2.5MetG (<italic>P</italic>&lt;0.001). From day-4, patients started getting daily increasing oral morphine intake, which was similar to the CG, DG and to the 2.5MetG from day-7 forwards (daily evaluation-<italic>P</italic>&gt;0.05). 7.5MetG=from day-1 to day-5, the daily intake of oral morphine was: 7.5MetG=7.5MetDG (<italic>P</italic>&gt;0.05) &lt;CG=DG=2.5MetG (<italic>P</italic>&lt;0.001). From day-6, patients started getting daily increasing oral morphine intake, which was similar to the CG, DG and to the 2.5MetG from day-10 forwards (daily evaluation-<italic>P</italic>&gt;0.05). 7.5MetDG=from day-1 to day-15, the daily intake of oral morphine was lesser when compared with the CG=DG=2.5MetG (<italic>P</italic>&lt;0.001). On day-4, 7.5MetDG &lt;5MetG (<italic>P</italic>&lt;0.05). On day-6, 7.5MetDG &lt;7.5MetG (<italic>P</italic>&lt;0.05). From day-15, the oral intake of daily morphine was similar to all groups (<italic>P</italic>&gt;0.05).</p></caption><graphic xlink:href="bjc2012593f1"></graphic></fig><table-wrap id="tbl1"><label>Table 1</label><caption><title>Demographic analysis</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="char" char="/"></col><col align="char" char="¬±"></col><col align="char" char="¬±"></col><col align="char" char="¬±"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">¬†</th><th align="center" valign="top" char="/" charoff="50"><bold>Gender (male/female)</bold><xref ref-type="fn" rid="t1-fn3">a</xref></th><th align="center" valign="top" char="¬±" charoff="50"><bold>Weight (kg)</bold><xref ref-type="fn" rid="t1-fn3">a</xref></th><th align="center" valign="top" char="¬±" charoff="50"><bold>Age (age)</bold><xref ref-type="fn" rid="t1-fn3">a</xref></th><th align="center" valign="top" char="¬±" charoff="50"><bold>Height (cm)</bold><xref ref-type="fn" rid="t1-fn3">a</xref></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">CG<hr></hr></td><td align="char" valign="top" char="/" charoff="50">3/5<hr></hr></td><td align="char" valign="top" char="¬±" charoff="50">58¬±11<hr></hr></td><td align="char" valign="top" char="¬±" charoff="50">53¬±14<hr></hr></td><td align="char" valign="top" char="¬±" charoff="50">165¬±9<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">DG<hr></hr></td><td align="char" valign="top" char="/" charoff="50">4/5<hr></hr></td><td align="char" valign="top" char="¬±" charoff="50">55¬±8<hr></hr></td><td align="char" valign="top" char="¬±" charoff="50">56¬±9<hr></hr></td><td align="char" valign="top" char="¬±" charoff="50">162¬±7<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">2.5MetG<hr></hr></td><td align="char" valign="top" char="/" charoff="50">4/6<hr></hr></td><td align="char" valign="top" char="¬±" charoff="50">57¬±7<hr></hr></td><td align="char" valign="top" char="¬±" charoff="50">53¬±11<hr></hr></td><td align="char" valign="top" char="¬±" charoff="50">167¬±9<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">5MetG<hr></hr></td><td align="char" valign="top" char="/" charoff="50">4/6<hr></hr></td><td align="char" valign="top" char="¬±" charoff="50">66¬±16<hr></hr></td><td align="char" valign="top" char="¬±" charoff="50">50¬±8<hr></hr></td><td align="char" valign="top" char="¬±" charoff="50">167¬±8<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">7.5MetG<hr></hr></td><td align="char" valign="top" char="/" charoff="50">5/5<hr></hr></td><td align="char" valign="top" char="¬±" charoff="50">56¬±13<hr></hr></td><td align="char" valign="top" char="¬±" charoff="50">52¬±13<hr></hr></td><td align="char" valign="top" char="¬±" charoff="50">164¬±6<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">7.5MetDG</td><td align="char" valign="top" char="/" charoff="50">5/6</td><td align="char" valign="top" char="¬±" charoff="50">54¬±12</td><td align="char" valign="top" char="¬±" charoff="50">47¬±13</td><td align="char" valign="top" char="¬±" charoff="50">162¬±6</td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><p>Abbreviations: CG=control group; DG=dexamethasone group; 2.5MetG=2.5‚Äâmg methadone group; 5MetG=5‚Äâmg methadone group; 7.5MetG=7.5‚Äâmg methadone group; 7.5MetDG=7.5‚Äâmg methadone-dexamethasone group.</p></fn><fn id="t1-fn2"><p><italic>P</italic>&gt;0.05.</p></fn><fn id="t1-fn3"><label>a</label><p>Data are expressed as mean¬±s.d.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2"><label>Table 2</label><caption><title>Distribution of the primary site of the cancer pathology and incidence of metastasis among the groups</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="char" char="."></col><col align="char" char="."></col><col align="char" char="."></col><col align="char" char="."></col><col align="char" char="."></col><col align="char" char="."></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">¬†</th><th align="center" valign="top" char="." charoff="50"><bold>CG (</bold><italic><bold>n</bold></italic><bold>=8)</bold></th><th align="center" valign="top" char="." charoff="50"><bold>DG (</bold><italic><bold>n</bold></italic><bold>=9)</bold></th><th align="center" valign="top" char="." charoff="50"><bold>2.5MetG (</bold><italic><bold>n</bold></italic><bold>=10)</bold></th><th align="center" valign="top" char="." charoff="50"><bold>5MetG (</bold><italic><bold>n</bold></italic><bold>=10)</bold></th><th align="center" valign="top" char="." charoff="50"><bold>7.5MetG (</bold><italic><bold>n</bold></italic><bold>=10)</bold></th><th align="center" valign="top" char="." charoff="50"><bold>7.5MetDG (</bold><italic><bold>n</bold></italic><bold>=11)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Oropharynx<hr></hr></td><td align="char" valign="top" char="." charoff="50">1<hr></hr></td><td align="char" valign="top" char="." charoff="50">1<hr></hr></td><td align="char" valign="top" char="." charoff="50">1<hr></hr></td><td align="char" valign="top" char="." charoff="50">2<hr></hr></td><td align="char" valign="top" char="." charoff="50">1<hr></hr></td><td align="char" valign="top" char="." charoff="50">1<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Breast<hr></hr></td><td align="char" valign="top" char="." charoff="50">3<hr></hr></td><td align="char" valign="top" char="." charoff="50">4<hr></hr></td><td align="char" valign="top" char="." charoff="50">4<hr></hr></td><td align="char" valign="top" char="." charoff="50">3<hr></hr></td><td align="char" valign="top" char="." charoff="50">3<hr></hr></td><td align="char" valign="top" char="." charoff="50">4<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Lung<hr></hr></td><td align="char" valign="top" char="." charoff="50">1<hr></hr></td><td align="char" valign="top" char="." charoff="50">0<hr></hr></td><td align="char" valign="top" char="." charoff="50">1<hr></hr></td><td align="char" valign="top" char="." charoff="50">0<hr></hr></td><td align="char" valign="top" char="." charoff="50">1<hr></hr></td><td align="char" valign="top" char="." charoff="50">0<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Uterus<hr></hr></td><td align="char" valign="top" char="." charoff="50">2<hr></hr></td><td align="char" valign="top" char="." charoff="50">1<hr></hr></td><td align="char" valign="top" char="." charoff="50">2<hr></hr></td><td align="char" valign="top" char="." charoff="50">1<hr></hr></td><td align="char" valign="top" char="." charoff="50">1<hr></hr></td><td align="char" valign="top" char="." charoff="50">2<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Prostate<hr></hr></td><td align="char" valign="top" char="." charoff="50">1<hr></hr></td><td align="char" valign="top" char="." charoff="50">2<hr></hr></td><td align="char" valign="top" char="." charoff="50">1<hr></hr></td><td align="char" valign="top" char="." charoff="50">2<hr></hr></td><td align="char" valign="top" char="." charoff="50">2<hr></hr></td><td align="char" valign="top" char="." charoff="50">2<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Digestive tract<hr></hr></td><td align="char" valign="top" char="." charoff="50">0<hr></hr></td><td align="char" valign="top" char="." charoff="50">0<hr></hr></td><td align="char" valign="top" char="." charoff="50">0<hr></hr></td><td align="char" valign="top" char="." charoff="50">1<hr></hr></td><td align="char" valign="top" char="." charoff="50">1<hr></hr></td><td align="char" valign="top" char="." charoff="50">1<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Kidney<hr></hr></td><td align="char" valign="top" char="." charoff="50">0<hr></hr></td><td align="char" valign="top" char="." charoff="50">0<hr></hr></td><td align="char" valign="top" char="." charoff="50">1<hr></hr></td><td align="char" valign="top" char="." charoff="50">0<hr></hr></td><td align="char" valign="top" char="." charoff="50">1<hr></hr></td><td align="char" valign="top" char="." charoff="50">0<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Liver<hr></hr></td><td align="char" valign="top" char="." charoff="50">7<hr></hr></td><td align="char" valign="top" char="." charoff="50">1<hr></hr></td><td align="char" valign="top" char="." charoff="50">0<hr></hr></td><td align="char" valign="top" char="." charoff="50">1<hr></hr></td><td align="char" valign="top" char="." charoff="50">0<hr></hr></td><td align="char" valign="top" char="." charoff="50">1<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Incidence of metastasis (%)</td><td align="char" valign="top" char="." charoff="50">63%</td><td align="char" valign="top" char="." charoff="50">66%</td><td align="char" valign="top" char="." charoff="50">60%</td><td align="char" valign="top" char="." charoff="50">70%</td><td align="char" valign="top" char="." charoff="50">60%</td><td align="char" valign="top" char="." charoff="50">73%</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><p>Abbreviations: CG=control group; DG=dexamethasone group; 2.5MetG=2.5‚Äâmg methadone group; 5MetG=5‚Äâmg methadone group; 7.5MetG=7.5‚Äâmg methadone group; 7.5MetDG=7.5‚Äâmg methadone-dexamethasone group.</p></fn><fn id="t2-fn2"><p><italic>P</italic>&gt;0.05.</p></fn><fn id="t2-fn3"><p>Incidence of metastasis at the time of inclusion at the study protocol.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3"><label>Table 3</label><caption><title>Number of patients who complained at day-7 and day-14 evaluation (total number of patients complaining per group)</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="char" char="."></col><col align="char" char="."></col><col align="char" char="."></col><col align="char" char="."></col><col align="char" char="."></col><col align="char" char="."></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">¬†</th><th align="center" valign="top" char="." charoff="50"><bold>CG</bold></th><th align="center" valign="top" char="." charoff="50"><bold>DG</bold></th><th align="center" valign="top" char="." charoff="50"><bold>2.5MetG</bold></th><th align="center" valign="top" char="." charoff="50"><bold>5MetG</bold></th><th align="center" valign="top" char="." charoff="50"><bold>7.5MetG</bold></th><th align="center" valign="top" char="." charoff="50"><bold>7.5MetDG</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Daily somnolence<sup>+</sup><hr></hr></td><td align="char" valign="top" char="." charoff="50">8<hr></hr></td><td align="char" valign="top" char="." charoff="50">9<hr></hr></td><td align="char" valign="top" char="." charoff="50">10<hr></hr></td><td align="char" valign="top" char="." charoff="50">9<hr></hr></td><td align="char" valign="top" char="." charoff="50">5<hr></hr></td><td align="char" valign="top" char="." charoff="50">1<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Nocturnal insomnia<hr></hr></td><td align="char" valign="top" char="." charoff="50">6<hr></hr></td><td align="char" valign="top" char="." charoff="50">7<hr></hr></td><td align="char" valign="top" char="." charoff="50">7<hr></hr></td><td align="char" valign="top" char="." charoff="50">7<hr></hr></td><td align="char" valign="top" char="." charoff="50">6<hr></hr></td><td align="char" valign="top" char="." charoff="50">5<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Nausea<hr></hr></td><td align="char" valign="top" char="." charoff="50">6<hr></hr></td><td align="char" valign="top" char="." charoff="50">5<hr></hr></td><td align="char" valign="top" char="." charoff="50">7<hr></hr></td><td align="char" valign="top" char="." charoff="50">6<hr></hr></td><td align="char" valign="top" char="." charoff="50">5<hr></hr></td><td align="char" valign="top" char="." charoff="50">2<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Vomiting<hr></hr></td><td align="char" valign="top" char="." charoff="50">2<hr></hr></td><td align="char" valign="top" char="." charoff="50">0<hr></hr></td><td align="char" valign="top" char="." charoff="50">2<hr></hr></td><td align="char" valign="top" char="." charoff="50">2<hr></hr></td><td align="char" valign="top" char="." charoff="50">2<hr></hr></td><td align="char" valign="top" char="." charoff="50">1<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Constipation<hr></hr></td><td align="char" valign="top" char="." charoff="50">8<hr></hr></td><td align="char" valign="top" char="." charoff="50">8<hr></hr></td><td align="char" valign="top" char="." charoff="50">8<hr></hr></td><td align="char" valign="top" char="." charoff="50">7<hr></hr></td><td align="char" valign="top" char="." charoff="50">8<hr></hr></td><td align="char" valign="top" char="." charoff="50">7<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Diminished appetite<hr></hr></td><td align="char" valign="top" char="." charoff="50">8<hr></hr></td><td align="char" valign="top" char="." charoff="50">6<hr></hr></td><td align="char" valign="top" char="." charoff="50">9<hr></hr></td><td align="char" valign="top" char="." charoff="50">10<hr></hr></td><td align="char" valign="top" char="." charoff="50">9<hr></hr></td><td align="char" valign="top" char="." charoff="50">1<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Fadigue<hr></hr></td><td align="char" valign="top" char="." charoff="50">8<hr></hr></td><td align="char" valign="top" char="." charoff="50">3<sup>+</sup><hr></hr></td><td align="char" valign="top" char="." charoff="50">10<hr></hr></td><td align="char" valign="top" char="." charoff="50">10<hr></hr></td><td align="char" valign="top" char="." charoff="50">10<hr></hr></td><td align="char" valign="top" char="." charoff="50">2<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Sadness</td><td align="char" valign="top" char="." charoff="50">8</td><td align="char" valign="top" char="." charoff="50">7</td><td align="char" valign="top" char="." charoff="50">10</td><td align="char" valign="top" char="." charoff="50">9</td><td align="char" valign="top" char="." charoff="50">10</td><td align="char" valign="top" char="." charoff="50">6</td></tr></tbody></table><table-wrap-foot><fn id="t3-fn1"><p>Abbreviations: CG=control group; 2.5MetG=2.5‚Äâmg methadone group; 5MetG=5‚Äâmg methadone group; 7.5MetG=7.5‚Äâmg methadone group; 7.5MetDG=7.5‚Äâmg methadone-dexamethasone group.</p></fn><fn id="t3-fn2"><p>Daily somnolence and appetite improved in the 7.5MetDG at day-7 and -14 evaluations (<italic>P</italic>&lt;0.005).</p></fn><fn id="t3-fn3"><p>Fatigue improved for DG and 7.5MetDG at day-7 and -14 (<italic>P</italic>&lt;0.005).</p></fn></table-wrap-foot></table-wrap></floats-group></article>